Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]

Banna, G L;Cortellini, A;Cortinovis, D L;Tiseo, M;Aerts, J G J V;Barbieri, F;Giusti, R;Bria, E;Grossi, F;Pizzutilo, P;Berardi, R;Morabito, A;Genova, C;Mazzoni, F;Di Noia, V;Signorelli, D;Gelibter, A;Macerelli, M;Rastelli, F;Chiari, R;Rocco, D;Gori, S;De Tursi, M;Di Marino, P;Mansueto, G;Zoratto, F;Filetti, M;Montrone, M;Citarella, F;Marco, R;Cantini, L;Nigro, O;D'Argento, E;Buti, S;Minuti, G;Landi, L;Guaitoli, G;Lo Russo, G;De Toma, A;Donisi, C;Friedlaender, A;De Giglio, A;Metro, G;Porzio, G;Ficorella, C;Addeo, A

2021-01-01